Edratide

Drug Profile

Edratide

Alternative Names: hCDR1; TV-4710

Latest Information Update: 07 Jan 2017

Price : $50

At a glance

  • Originator Weizmann Institute of Science
  • Developer Teva Pharmaceutical Industries; XTL Biopharmaceuticals
  • Class Peptide fragments
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus
  • Research Sjogren's syndrome

Most Recent Events

  • 05 Jan 2017 Early research in Sjogren's syndrome in Israel (unspecified route)
  • 05 Jan 2017 XTL Biopharmaceuticals files for patent protection with U.S. Patent and Trademark Office for Edratide
  • 07 Sep 2016 XTL Biopharmaceuticals receives patent allowance for Edratide in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top